University of Health Sciences, Gulhane Medical School, Ankara, Turkey.
Department of Infectious Diseases and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey.
J Infect Dev Ctries. 2024 Feb 29;18(2):188-194. doi: 10.3855/jidc.17927.
Coronavirus disease 2019 (COVID-19) can have symptoms like many neurological diseases, and one of the rare forms of these presentations is opsoclonus-myoclonus ataxia syndrome (OMAS). The pathogenesis of OMAS in adults has not been clearly elucidated and OMAS can be fatal.
We present a 71-year-old male patient who was admitted to the emergency department with complaints of involuntary tremor-like movements in his hands, feet and mouth, and speech impediment for three days, and was followed up with COVID-19. The patient was diagnosed with OMAS and clonazepam treatment was started. He died three days later due to respiratory arrest. Our case is the first case diagnosed with COVID-19-associated OMAS in Turkey.
OMAS has no definitive treatment. Early diagnosis and initiation of corticosteroids and intravenous immunoglobulin (IVIG) therapy, if necessary, can be life-saving. In COVID-19 patients with unexplained clinical findings, awareness of different and rare diseases and a multidisciplinary approach has vital importance.
新型冠状病毒病 2019（COVID-19）可引起多种类似神经系统疾病的症状，这些表现中较为罕见的一种是眼-口-肌阵挛-共济失调综合征（OMAS）。成人 OMAS 的发病机制尚未明确，且 OMAS 可能是致命的。
我们报告了一例 71 岁男性患者，因手部、足部和口腔不自主震颤样运动以及言语障碍三天而被收入急诊，同时患者有 COVID-19 接触史。该患者被诊断为 OMAS，开始给予氯硝西泮治疗。三天后因呼吸骤停死亡。我们的病例是土耳其首例确诊的 COVID-19 相关 OMAS 病例。
OMAS 尚无明确的治疗方法。早期诊断以及尽早开始皮质类固醇和静脉注射免疫球蛋白（IVIG）治疗（如有必要）可能是救命的。对于 COVID-19 患者，在出现不明原因的临床发现时，注意不同的罕见疾病并采取多学科方法至关重要。
